About the Study

Focal Segmental Glomerulosclerosis (FSGS): A study of a medication called DMX 200 (repagermanium)

This study is being done for patients: • 18 and 80 years of age • Diagnosed with focal segmental glomerulosclerosis (FSGS). • Have been taking an ARB before the start of the study or are willing to start ARB treatment The main purpose of this study is to see if the medication DMX-200 (repagermanium) reduces protein from the blood to collect in the urine (proteinuria) and slows the loss of kidney function when taken at the same time as the drugs called angiotensin II receptor blockers (ARB) that work by reducing blood pressure and improving kidney function.

Interested in learning more?

Full Study Name: Dimerix (Action3)